Compare MSS & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSS | PFSA |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.1K | 902.5K |
| IPO Year | 2023 | 2021 |
| Metric | MSS | PFSA |
|---|---|---|
| Price | $0.91 | $0.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 59.9K | ★ 1.8M |
| Earning Date | 12-21-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.84 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $124,217,480.00 | $100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 114.01 | N/A |
| 52 Week Low | $0.42 | $0.42 |
| 52 Week High | $580.00 | $45,495.00 |
| Indicator | MSS | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 34.41 | 32.49 |
| Support Level | $0.42 | N/A |
| Resistance Level | $1.21 | $1.35 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.00 | 0.14 |
| Stochastic Oscillator | 15.00 | 10.33 |
Maison Solutions Inc is a fast-growing, specialty grocery retailer offering traditional Asian food and merchandise to modern U.S. consumers, particularly members of Asian-American communities. It is committed to providing Asian fresh produce, meat, seafood, and other daily necessities in a manner that caters to traditional Asian-American family values and cultural norms, while also accounting for the new and faster-paced lifestyle of younger generations and the diverse communities in which it operates. The company's merchandise includes fresh and, meats, seafood, and other groceries that are not found in mainstream supermarkets, including a variety of Asian vegetables and fruits such as broccoli, bitter melon, winter gourd, Shanghai baby bok choy, longan, and lychee.
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.